Koenig Scott
Known title: President and CEOCIK: 0001587514
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
Transaction History
| MGNX | ▲ Buy | Option Exercise | 21,165 | $0 | 2/15/2026 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 15,831 | — | 2/8/2026 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 21,165 | $0 | 8/13/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 31,664 | $0 | 8/13/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 42,329 | $0 | 2/15/2025 | View on chart |
| MGNX | ▲ Buy | Grant | 31,673 | $0 | 2/8/2025 | View on chart |
| MGNX | ▼ Sell | Gift | 53,265 | — | 10/7/2024 | View on chart |
| MGNX | ▼ Sell | Gift | 53,265 | — | 10/7/2024 | View on chart |
| MGNX | ▼ Sell | Gift | 374,215 | — | 9/23/2024 | View on chart |
| MGNX | ▼ Sell | Gift | 374,215 | — | 9/23/2024 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 42,341 | $0 | 2/15/2024 | View on chart |
| MGNX | ▼ Sell | Tax Withholding | 14,349 | $250K | 2/15/2024 | View on chart |
| CBIO | ▲ Buy | Option Exercise | 21,000 | $13K | 6/1/2023 | View on chart |
| CBIO | ▲ Buy | Option Exercise | 10,500 | $27K | 1/27/2023 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 53,265 | $80K | 5/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review
MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.